The duration of market exclusivity can vary. In the United States, new drugs can be granted five years of exclusivity, with potential extensions for specific circumstances, such as pediatric studies. Additionally, orphan drugs, which treat rare conditions, can receive up to seven years of exclusivity. The European Union offers similar exclusivity periods but with some differences in regulations and extensions.
